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Abstract 
Cutaneous diffuse B-cell lymphoma leg type is a rare entity, it 
represents approximately 5% of primary cutaneous lymphomas. It has a poor 
prognosis. We report case of t 58 years old patient with a cutaneous B cell 
lymphoma leg type with dual location at the upper and lower limbs and bone 
lysis. Histological examination of the skin biopsy showed diffuse 
lymphomatous proliferation dissecting collagen, made of large cells with 
abundant cytoplasm moderately ill-defined, ovoid nuclei and with a discreet 
nuclear irregularity. The immunohistochemical study revealed lymphoma 
cells phenotype B with a homogeneous expression of CD 20, a homogeneous 
expression of CD 3, CD 43 positive. Bcl 2 was positive, as the Bcl 6 and Mum 
1. CD 5, CD10, MPO, CD 34, and Tdt were negative. The Ki 67 was 
positivein90%. The staging showed extensive osteolysis of the lower end of 
the humerus and the ulna. The patient received 2 courses RCHOP, with 
faillure of treatment, and then she received one course of RDHAP before 
dying.  The particularity of this observation consists in the age; our patient 
was younger than the average, and the double localization of lymphoma in 
both arm and leg, with osteolysis. We discuss also the difficulties of treatment 
of this disease. 
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Introduction 
Cutaneous large B-cell lymphoma leg type is a rare entity, accounting 
for about 5% of primary cutaneous lymphomas (Brouillard et al, 2011). It 
essentially affects the elderly subject. Clinically, "leg-type" cutaneous B-cell 
lymphoma is manifested by nodular or tumoral lesions that are generally 
erythematous and preferentially sit on the legs (Willemze, 2005). The 
diagnosis is based on the anatomopathological study coupled with 
immunohistochemical study of the skin biopsy. Extra-cutaneous 
dissemination is rare. It has a poor prognosis, and the 5-year survival is 58%. 
The treatment is based essentially on a multidrug therapy combined with 
Rituximab. 
We report the case of a 58-year-old patient with cutaneous cutaneous 
B-cell lymphoma with localization in both the lower and upper limbs and 
associated bone involvement. 
 
Case report 
A 58-year-old patient had consulted for an isolated swelling appeared 
7 months before her admission in the left leg without an associated B sign at 
first time (Figure 1).  
 
Figure 1: lesion initiale au niveau de la face anterieure de la jambe gauche 
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The clinical evolution was marked by the rapid onset of other swelling 
of the left leg, gradually increasing volume, as well as the appearance of other 
swelling in the right elbow. These lesions were painless and non-pruriginous. 
In addition, the patient reported the notion of fever and anorexia associated 
with unencrypted weight loss. The clinical examination had found a tired 
patient, Performans Status at 3, apyretic. The examination found 3 nodular 
lesions in the left leg, the largest of which was 10/10 cm (Figure 2), 9/8 cm 
ulcero-necrotic lesion in the right leg (Figure 3), and lesion opposite the right 
elbow with collateral circulation opposite (Figure 4), and last 2 lesions of the 
left buttock measuring respectively 3cm and 2 cm. At this stage, the 
diagnostic discussion focused on the type of lymphoma: non-Hodgkin's 
anaplastic lymphoma or cutaneous B-type skin lymphoma. 
 
Figure 2: 3 lesions au niveau de la jambe gauche 
 
Figure 3: lesion ulcero-bourgeonnante de la jambe droite 
European Scientific Journal March 2019 edition Vol.15, No.9 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
240 
 
Figure 4: lesion au niveau du coude avec circulation collaterale en regard et peau luisante 
 
Diagnostic confirmation of cutaneous cutaneous B-cell lymphoma 
was made by the anatomopathological study of the cutaneous biopsy which 
showed diffuse lymphomatous proliferation dissecting collagen, made of 
large cells, with a moderately abundant, poorly defined cytoplasm, and ovoid 
nuclei with a discreet nuclear irregularity. The immunohistochemical study 
revealed lymphoma cells of phenotype B, with a homogeneous expression of 
CD 20, a homogeneous expression of CD3, a positive CD43. Bcl 2 was 
positive, as well as Bcl 6 and Mum 1. CD 5, CD 10, MPO, CD 34, and Tdt 
were negative. Ki 67 was 90% positive. 
The biological assessment revealed a microcytic hypochromic anemia 
at 8.2 g / dl, without other abnormalities of the hemogram. The albumin level 
was normal. Hepatic and renal functions were preserved. Viral serology 
(HIV, HVB and HCV) were negative. The rate of D-Dimers was normal. 
Electrophoresis of the proteins was normal. The standard radiograph of the 
elbow had found a CT-confirmed osteolysis of the elbow which had revealed 
extensive osteolysis of the lower extremity of the humerus and the superior 
end of the ulna with invasion of the elbow and a tissue mass of 11.5 / 10 / 7.5 
cm (Figure 5). 
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Figure 5: Lyse osseuse de l’extrenute ubferueyre de l’humerus et l’extremite superieure du 
cubitus 
 
The bone scintigraphy had demonstrated hyperfixation of the 
humeral, elbow and left and right leg. Standard chest X-ray was normal. 
Abdominal ultrasound was normal. The thoraco-abdominopelvic CT had not 
found deep localizations. The bone marrow biopsy had not found any signs 
of infiltration. The left ventricular ejection fraction was at 64%. The 
chemotherapy protocol adopted was that of R-CHOP consisting of 
Rituximab, cyclophosphamide, vincristine and Prednisone, combined with a 
prophylactic intrathecal injection. The evolution after 2 courses was marked 
by a fast but transient tumor slit. Indeed, before administering the 3rd course, 
the lesions were progressive, with an increase in the volume of pre-existing 
nodules and the appearance of new lesions. It was decided to switch to 
second-line chemotherapy. The patient received a first R-DHAP course made 
of Rituximab, high-dose Aracytine, Cisplatin and Dexamethasone after which 
her general condition had rapidly and profoundly altered. And the patient died 
soon after. 
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Discussion 
Cutaneous B-cell lymphoma "large-cell type" is a rare entity, it mainly 
affects the elderly: 80% of patients are over 70 years old (Brouillard, 2011). 
It reaches preferentially the female sex (3 women / 1 man). Clinically, it is 
manifested by infiltrated nodules or plaques generally occurring in the lower 
limb. The observation we report is characterized by the occurrence of 
lymphoma in a relatively young patient. The other particularity is the nodular 
involvement occurring both at the level of the 2 lower limbs but also at the 
level of the upper limb associated with osteolytic bone involvement. 
The diagnosis of cutaneous large B-cell lymphoma "leg type" should 
not be retained on the topography of the lesions. In fact, eight cases of cerebral 
localization of cutaneous large-cell cutaneous B-cell lymphoma have been 
reported in the literature, two of which were initial sites and six of brain 
relapses (Gardette, 2016). 
The diagnosis must therefore be confirmed by a morphological study 
of the cutaneous biopsy which shows a diffuse and dense, non-
epidermotropic, monomorphic dermal infiltrate made of large lymphoid cells 
with rounded cores of centroblastic and / or immunoblastic type 
(Wechsler,2000; Hoefnagel, 2006) . The lymphoma cells generally express B 
lymphocyte markers (CD20, CD79a), BCL2, MUM1 / IRF4, but not the 
CD10 centrogerminative origin marker (Willemze, 2005; Wechsler, 2000). 
In the past the nature of lymphocyte B of this type of lymphoma was 
unclear, it was considered a lymphocyte of the germinal center, however a 
recent study of clonality was performed on DNA extracted from skin biopsy 
of 17 patients followed for cutaneous lymphone B at large "leg-type" cell, the 
analysis of the structure and sequence of the IGHV, IGKV, or IGLV genes 
showed that the original cell could be a mature B lymphocyte that has 
undergone the phenomenon of somatic hypermutation at the level of from the 
germinal center, it would therefore be a mature B lymphocyte ( Pham-
Ledard 2014;7 Pham-Ledard,2013). 
No risk factor has been identified as a predictive factor in the 
occurrence of cutaneous large B-cell lymphoma, however, a few cases have 
been reported in the literature related to the occurrence of cutaneous B-cell 
lymphoma leg type "on pre-existing lesions such as burns, shingles or 
amputation stump (Brouillard, 2011; Meziane 2009). Other published cases 
have described the occurrence of this type of lymphoma on a leg ulcer, 
without any cause being retained as directly related to the development of 
lymphoma (Brogan, 2003). 
Another peculiarity of this type of lymphoma is the presence of the 
activating mutation of the gene MYD88 L265P, this mutation would be 
present in 69% of cases, and it would be associated with factors related to the 
disease, including localization in the leg, and a advanced age. On the other 
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hand, the high prevalence of the MYD88 L265P mutation in this lymphoma 
would have a pejorative prognostic value (Pham-Ledard, 2014). 
The prognosis of cutaneous type B-type skin lymphoma is poor 
(Grange, 2007; Grange, 2009). However, preferential localization at the level 
of the legs is better prognosis; the extra-cutaneous extension is relatively 
frequent (17 to 43%) (Brouillard, 2011). In our observation the extra-
cutaneous involvement was in bone which remains relatively rare. 
The treatment depends on the number of lesions (Torres-Paoli,2000) 
in localized forms, radiotherapy can be proposed. In the extended or 
multifocal forms, a poly-chemotherapy combining Rituximab and a CHOP or 
mini CHOP is the reference treatment. 
Indeed, the combination of Rituximab with a poly-chemotherapy 
containing anthracyclines would give a percentage of complete responses 
approaching 90% (Grange,2007). Rituximab alone or used in combination 
with chemotherapy allows remissions, however relapse is common, hence the 
use of Rituximab maintenance has been considered, and this maintenance 
treatment seems to prevent recurrence as long as it is maintained , except that 
it is necessary to have more study justifying the use of Rituximab in 
maintenance (Becourt,2011). 
However, this chemotherapy is not always possible for these patients 
in the advanced age, and often associated heart disease explaining the 
difficulties to properly manage this type of lymphoma and therapeutic escape 
often reported. 
In case of failure or relapse, the therapeutic options are even more 
limited in front of the fragile field of these patients, and the aggressiveness of 
the lymphoma. A multi-center phase II clinical trial was conducted in GFELC 
to evaluate Lenalidomide for the treatment of diffuse large-cell B-cell diffuse 
relapsing or failing lymphoma after a first Rituximab-based therapeutic line 
with chemotherapy, the response was considered modest not allowing its use 
in the first line, and the occurrence of many side effects justified the dose 
reduction, other tests are necessary before the proposal of Lenalidomide for 
the treatment of B lymphomas Large-cell "leg-type" (Mermin ,2016; 
Descamps, 2011) and other studies are underway for the evaluation of 
lenalidomide as a second-line therapy alone or in combination with 
dexamethasone in the treatment of cutaneous large B-cell lymphoma leg type. 
 
Conclusion 
This manuscript presents an important clinical condition that is 
uncommon and is characterize by the young age of our patient; and the 
agressivity of this lymphoma and highlights the difficulties to manage this 
type of lymphoma. 
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